Cirius Therapeutics Inc., of San Diego, reported preclinical data showing stellate cell activation and expression of markers of fibrosis were reduced when mitochondrial pyruvate carrier was deleted from liver cells or when mitochondrial pyruvate carrier was attenuated with Cirius’ drug MSDC-0602K, which modulates the entry of pyruvate into the mitochondria.